RNA sequencing reveals early apoptosis and immune activation in LM patients treated with REYOBIQ, highlighting its therapeutic potential and long-term survival benefits in central nervous system cancers…
RNA sequencing data shows clinical benefit and safety of Plus Therapeutics’ REYOBIQ™
Share.
